Dexisun 100,0 μg CONCENTRATED SOLUTION FOR INTRAVENOUS INFUSION
PDF Leaflet Revision Date: 21 June 2022
Clinical Summary
Quick overview from the medicine insert
Indication
ICU sedation and monitored anaesthesia care.
Dosage (summary)
Loading: 1 mcg/kg over 10 mins; Maintenance: 0.2-0.7 mcg/kg/h.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy or lactation.
Key Drug Interactions
- Enhanced effects with sedatives and opioids
- Caution with beta blockers
Contraindications
- Hypersensitivity to dexmedetomidine
- Sepsis
- Unstable trauma
- Hypovolaemia
- Heart block
- Uncontrolled cardiac failure
- Imminent hepatic failure
- Uncontrolled hypotension
- Acute cerebrovascular conditions
Common side effects
- Hypotension
- Bradycardia
- Nausea
- Dry mouth
- Hypoxia
Counselling Points
- Avoid driving for 24 hours post-sedation
- Refrain from sedatives and alcohol post-procedure
Serious warnings
- Continuous monitoring required during infusion
- Risk of bradycardia and sinus arrest
Important Disclaimer
The Dexisun 100,0 μg CONCENTRATED SOLUTION FOR INTRAVENOUS INFUSION professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
